Vivani Medical, Inc. VANI PHARMA

Q: What is the current share price of Vivani Medical, Inc. (VANI)?

As of 2026-09-19 21:16 PDT, Vivani Medical, Inc. (VANI) trades at $1.36 on NasdaqCM. Its 52-week range is $0.94 to $1.87.

Q: What is the market capitalisation of VANI?

Vivani Medical, Inc. (VANI) has a market capitalisation of $122.68M on NasdaqCM.

Q: What is the P/E ratio of VANI?

VANI trades at a trailing price-to-earnings (P/E) ratio of -3.89. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.61.

Q: Is VANI a good stock to buy?

This page provides a data-driven analysis of Vivani Medical, Inc. (VANI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Biotechnology · United States

https://www.vivani.com

Company Profile ↓

$1.36

+7.54% 1Y

Mkt Cap$122.68M

P/E-3.89

P/B5.61

52W High$1.87

52W Low$0.94

Book Value$0.21

EPS (TTM)$-0.35

Company Overview

Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases. Its pipeline includes NPM-139 for chronic weight management in patients who are obese or overweight; NPM-133 a semaglutide implant for the treatment of patients with type 2 diabetes; NPM-115, an exenatide implant candidate for chronic weight management in patients who are obese or overweight; and OKV-119, an exenatide implant for the treatment of obesity and diabetes in companion animals, including cats and dogs. The company is headquartered in Alameda, California.

Growth & Price Performance

Stock Price Performance

1 Year:	+7.54%
6 Months:	+15.81%
3 Months:	+17.83%
1 Month:	-3.90%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed

52-Week Range 45% of range

$0.94 $1.87

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMAAbove
RSI (14)47.46 · Neutral

Price Performance

1M-3.90%

3M+17.83%

6M+15.81%

1Y+7.54%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

In a confirmed uptrend (50-DMA above 200-DMA).

CONS

Trading 27.5% below its 52-week high.

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-3.89

Industry PE

24.83

Forward P/E

-3.89

PEG Ratio

Book Value

$0.21

Price to Book

5.61

P/S

EV/EBITDA

-3.93

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

Profit 5Y

Revenue (YoY)

Earnings (YoY)

Profitability & Returns

ROCE

-84.04%

ROE

ROA

-48.47%

Profit Margin

0.00%

Op Margin

0.00%

Gross Margin

0.00%

EPS (Latest Qtr)

$-0.08

EPS (TTM)

$-0.35

Balance Sheet & Liquidity

Debt/Equity

0.94

Quick Ratio

3.09

Current Ratio

3.25

Debt

$17.86M

Total Assets

$42.35M

Current Assets

$21.55M

Working Capital

$11.30M

Ownership

Promoter Holding

55.39%

Chg in Prom Hold

-2.55%

FII / Inst Holding

5.89%

Chg in FII Hold

-0.62%

Financial Snapshot

Enterprise Value

$122.68M

Total Revenue (TTM)

EBITDA

$-26.88M

Free Cash Flow

$-16.83M

Operating Cash Flow

$-25.30M

Shares Outstanding

90.20M

Gross Margin

0.00%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	VANI Vivani Medical, Inc. PHARMA	1.36	-3.89	$122.68M	0.00%	-84.04%	-	-	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Dec 2015	Mar 2016	Jun 2016	Sep 2016	Dec 2016	Mar 2017	Jun 2017	Sep 2017	Dec 2017	Mar 2018	Jun 2018	Sep 2018	Dec 2018	Mar 2019	Jun 2019	Sep 2019	Dec 2019	Mar 2020	Jun 2020	Sep 2020	Dec 2020	Mar 2021	Jun 2021	Sep 2021	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	1.05K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	691.00K	141.00K	-2.20M	-1.44M	-2.59M	-118.00K	-1.11M	609.00K	1.25M	308.00K	1.07M	462.00K	167.00K	397.00K	349.00K	108.00K	373.00K	-	0	-	500.00K	-	0	-	130.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	6.56M	7.46M	6.72M	6.81M	6.82M
Operating Income	-5.48M	-5.82M	-8.51M	-8.50M	-10.38M	-7.55M	-6.87M	-6.75M	-7.43M	-9.77M	-7.99M	-8.55M	-8.88M	-9.77M	-8.44M	-7.62M	-8.13M	-8.90M	-3.12M	-1.60M	-1.27M	-2.84M	-2.30M	-3.48M	-1.29M	-3.91M	-4.09M	-5.44M	-6.60M	-7.00M	-7.14M	-6.23M	-5.68M	-6.31M	-	-6.56M	-7.46M	-6.72M	-6.81M	-6.82M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.46M	-7.36M	-6.62M	-6.70M	-6.69M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-6.30M	-7.14M	-6.53M	-6.63M	-6.78M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-5.47M	-5.82M	-8.50M	-8.49M	-10.37M	-7.55M	-6.84M	-6.72M	-7.41M	-9.75M	-7.96M	-8.52M	-8.86M	-9.70M	-8.44M	-7.58M	-7.87M	-8.89M	-3.10M	-1.60M	-1.29M	-2.99M	-2.67M	-3.49M	-1.28M	-3.92M	-4.10M	1.42M	-6.32M	-6.53M	-6.78M	-6.04M	-5.36M	-6.04M	-	-6.30M	-7.14M	-6.53M	-6.63M	-6.78M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.10	-	-	-	0.04	-	-0.13	-0.13	-0.12	-0.10	-0.11	-0.11	-0.11	-0.12	-0.11	-	-0.08
R&D Expense	-	762.00K	916.00K	1.59M	-	1.85M	1.95M	1.83M	-	2.47M	2.42M	2.67M	-	2.18M	3.44M	3.38M	-	3.89M	323.00K	279.00K	-	334.00K	695.00K	2.87M	-	2.68M	3.20M	3.86M	3.96M	3.86M	4.44M	3.73M	3.51M	4.20M	-	4.22M	4.76M	4.52M	-	4.39M

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	1.56M	3.40M	8.90M	4.00M	7.96M	6.90M	3.38M	-	-	0	0	0	0
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-
Gross Profit	-4.06M	-160.00K	3.66M	-6.09M	2.85M	2.01M	1.23M	500.00K	-	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	21.24M	26.96M	24.68M	27.56M
Operating Income	-18.00M	-21.23M	-20.05M	-33.21M	-28.61M	-35.18M	-33.95M	-14.90M	-	-21.24M	-26.96M	-24.68M	-27.56M
EBITDA	-	-	-	-	-	-	-	-	-	-20.86M	-26.61M	-24.28M	-27.13M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-13.89M	-25.65M	-23.49M	-26.61M
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-22.97M	-35.20M	-20.02M	-33.18M	-28.52M	-35.09M	-33.59M	-14.88M	-	-13.89M	-25.65M	-23.49M	-26.61M
Diluted EPS	-	-	-	-	-	-	-	-	-	-0.36	-0.50	-0.43	-0.43
R&D Expense	3.25M	5.04M	3.04M	5.35M	7.89M	10.01M	13.14M	4.84M	11.00M	14.17M	16.97M	15.74M	18.13M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	-	43.07M	28.25M	16.81M	14.50M	10.68M	16.60M	4.46M	-	51.13M	45.80M	41.56M	39.39M
Current Assets	-	-	-	-	-	-	-	-	-	-	47.53M	23.06M	20.44M	17.90M
Cash & Equivalents	145.00K	62.00K	619.00K	15.96M	10.88M	7.84M	4.47M	11.33M	3.18M	-	45.08M	20.65M	18.35M	16.23M
Inventory	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Receivables	-	-	-	-	-	-	-	-	-	-	-	0	253.00K	654.00K
Total Liabilities	-	-	-	-	-	-	7.60M	9.32M	5.13M	-	6.82M	25.04M	23.95M	23.66M
Current Liabilities	-	-	8.45M	7.98M	5.66M	6.62M	7.60M	6.96M	5.13M	-	6.82M	5.72M	5.99M	6.60M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	955.00K	20.70M	19.31M	18.86M
Total Equity	-3.04M	-9.22M	34.62M	20.26M	11.15M	7.88M	3.08M	7.28M	1.95M	-	44.31M	20.76M	17.61M	15.73M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	50.74M	51.03M	59.23M	76.43M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	-20.55M	-25.07M	-23.95M	-29.81M	-27.63M	-16.82M	-	-18.79M	-23.70M	-20.79M	-24.32M
Investing Cash Flow	-4.55M	-25.95M	17.52M	-490.00K	-265.00K	-163.00K	-493.00K	68.00K	-	-338.00K	-887.00K	-556.00K	-1.17M
Financing Cash Flow	21.97M	43.80M	2.76M	20.45M	21.17M	26.60M	34.99M	8.60M	-	63.39M	133.00K	19.05M	23.27M
Capital Expenditure	-246.00K	-560.00K	-762.00K	-490.00K	-265.00K	-163.00K	-493.00K	-330.00K	-	-338.00K	-887.00K	-556.00K	-1.17M
Free Cash Flow	-	-	-21.31M	-25.56M	-24.21M	-29.97M	-28.12M	-17.15M	-	-19.12M	-24.59M	-21.34M	-25.49M
Net Change in Cash	-	-	-	-	-	-	-	-	-	44.27M	-24.45M	-2.29M	-2.22M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	-259.7%	-4.7%	41.1%	-152.3%	35.7%	29.1%	36.3%	-	-	-	-	-	-
Operating Margin %	-1,150.0%	-624.5%	-225.2%	-830.2%	-359.2%	-510.2%	-1,004.9%	-	-	-	-	-	-
Net Margin %	-1,467.7%	-1,035.3%	-224.9%	-829.5%	-358.1%	-508.9%	-994.1%	-	-	-	-	-	-
ROE %	249.1%	-101.7%	-98.8%	-297.6%	-361.8%	-1,137.9%	-461.7%	-763.1%	-	-31.3%	-123.6%	-133.4%	-169.2%
ROCE %	-	-61.3%	-98.9%	-297.9%	-363.0%	-1,140.7%	-352.2%	2,216.7%	-	-47.9%	-67.3%	-69.4%	-84.0%

Shareholding Pattern

Insiders

55.39%

Institutions

5.89%

Public Float

13.21%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Vanguard Capital Management LLC	1.96%	1.77M	$2.10M
2	Tanager Wealth Management LLP	0.67%	607.28K	$722.66K
3	Geode Capital Management, LLC	0.65%	587.75K	$699.42K
4	Tudor Investment Corp Et Al	0.46%	410.90K	$488.97K
5	Commonwealth Equity Services, LLC	0.37%	330.56K	$393.37K
6	Vanguard Fiduciary Trust Co	0.36%	325.46K	$387.30K
7	Blackrock Inc.	0.33%	301.83K	$359.18K
8	Monetary Management Group, Inc.	0.22%	193.98K	$230.83K
9	State Street Corporation	0.17%	154.97K	$184.41K
10	Northern Trust Corporation	0.13%	116.91K	$139.12K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VANI

Google News hu, 03 Sep 2026

Two New York conferences are planned for Vivani Medical - Stock Titan

<a href="https://news.google.com/rss/articles/CBMitAFBVV95cUxQakFzaUVPamdvQUZGcV8ydnRiM1FkNlAxSXl2VVZvdnVleWhZSmJZQjRYNkVXSFNJUFczS2gxUzVma1pTV3RZazNPbV8wZi1yR1J5UjhheFJWdXdoNFZBM1U3bXJnelNiNk9jUk8zakgtT2ppc2NPZnJhTXlhZEpDNFk4cUV3by1uYjlDYz…

Google News hu, 03 Sep 2026

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxOTXRCai1CVjdWOE9xVm1HajV5S2FwSlQ3VXNkUklyVVV0dndYRW1UVjE5UFhFZFNrTTJUSHVNS3VaQkF5dHRrRmpkN0ZRZ3FYRXpHeXM3Q04yY2p0ZjA2RTdmSXk5TGhrODZsdDdCLVpjeUlROG9CWUQ5d1p1UEFXeVg0WmUyai1SVURaVE…

Google News hu, 13 Aug 2026

Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - marketbeat.com

<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcV9PUi1pdW9hYWhHMFBGUFFHaWlWLUhPbUVFbUZkMndGbjQwTEp6bk1xVGRQNTJRdXY4R3BwbGU0YXBaUGVSaE5nTFpFRkdwUU9hOVVwYWl6MUl1eDFrUE5JMm0wV0RlNTdiTWNkOUpmZVFESl9sYUZFVUROVVBuendZZlhuUVljMS1iRn…

Google News hu, 13 Aug 2026

Vivani Medical: Q2 Earnings Snapshot - ktvb.com

<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxOcXBNT0gwYU02TXF5bXlhbTlPSi1SX2tJNXEtcXYzR3ZRdTRzX1d2REk0dUI4T3dkV2VSbmNpZ25TSEVlUEVwdUdrd0FKYUNfUUJfYlF0TGdhRW9yVGNNWWpxY2lsNERTY3NzRlctQVNUekgtZGZYWGh1bC1ObXlVSGNPc3JYRFdwQnlBb3…

Google News Fri, 03 Apr 2026

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxPanplVnRHNFJlZzFCcmRsOGJrb2xUOG1HMkJnUEJFcjExMlRyYmU3Znh6NkctbjZaUVBkeHZvb3Q1dkw0RWlHZWpiRk1CYTl2NWdQcHJZUGVCZkp0UnVzNi1NR0oxSjA0elBULXlSaFF1VjFmQkxSV0Vmcy1tV0xSbVVMdG5EZ3kxYXIteD…

Google News hu, 16 Jul 2026

Vivani Medical director Gregg Williams buys $1m in stock - Investing.com

<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxPVUNYdzh0a1hrXzlodGJDLUVXNmRRU1plWGc2RURkaGltMWtHSmJ4RUdDWTBMd3VRLW43Y1RmUEc2QS1NLW9uNlBDODZ0SjFMYkY2ZW5DUm9BNVgtNE1uMzBpLVJoUFZGWFhUanJEUUtyTUozWnFwR1QwRTZjNldZMmlVUlBhTEQxenlRSj…

VANI — Frequently Asked Questions

What is the current share price of Vivani Medical, Inc. (VANI)?

As of 2026-09-19 21:16 PDT, Vivani Medical, Inc. (VANI) trades at $1.36 on NasdaqCM. Its 52-week range is $0.94 to $1.87.

What is the market capitalisation of VANI?

Vivani Medical, Inc. (VANI) has a market capitalisation of $122.68M on NasdaqCM.

What is the P/E ratio of VANI?

VANI trades at a trailing price-to-earnings (P/E) ratio of -3.89. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 5.61.

Is VANI a good stock to buy?

This page provides a data-driven analysis of Vivani Medical, Inc. (VANI), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Vivani Medical, Inc. VANI PHARMA

Company Overview

Growth & Price Performance

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

Two New York conferences are planned for Vivani Medical - Stock Titan

Vivani Medical to Participate in Upcoming Lake Street and H.C. Wainwright Investor Conferences - Quiver Quantitative

Vivani Medical (NASDAQ:VANI) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS - marketbeat.com

Vivani Medical: Q2 Earnings Snapshot - ktvb.com

Vivani Medical (VANI) Upgraded to Buy: What Does It Mean for the Stock? - finance.yahoo.com

Vivani Medical director Gregg Williams buys $1m in stock - Investing.com

VANI — Frequently Asked Questions

What is the current share price of Vivani Medical, Inc. (VANI)?

What is the market capitalisation of VANI?

What is the P/E ratio of VANI?

Is VANI a good stock to buy?

Explore More